Free tool
FAERS Monitor: Femara
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020726 or its brand name (Femara, Letrozole). Reports on generic versions are filed under their own applications.
Reports
62,445
Serious
50,509
81% of reports
Hospitalization
15,972
Death reported
6,134
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue7,561
- nausea5,594
- neutropenia5,295
- diarrhoea4,792
- malignant neoplasm progression4,614
- arthralgia4,046
- white blood cell count decreased3,845
- alopecia3,711
- pain3,097
- asthenia3,034
- dyspnoea2,976
- vomiting2,820
- neoplasm progression2,791
- death2,738
- headache2,537
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 155 |
| 2005 | 305 |
| 2006 | 463 |
| 2007 | 438 |
| 2008 | 515 |
| 2009 | 606 |
| 2010 | 934 |
| 2011 | 1,099 |
| 2012 | 1,083 |
| 2013 | 869 |
| 2014 | 827 |
| 2015 | 1,937 |
| 2016 | 3,080 |
| 2017 | 3,344 |
| 2018 | 4,475 |
| 2019 | 5,738 |
| 2020 | 5,880 |
| 2021 | 6,044 |
| 2022 | 5,875 |
| 2023 | 5,949 |
| 2024 | 5,025 |
| 2025 | 4,538 |
| 2026 | 3,266 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,991,714 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 2,791 | 29.3 | 28.2 | 70,295 |
| malignant neoplasm progressionSignal | 4,614 | 15.8 | 15.4 | 61,562 |
| neutropeniaSignal | 5,295 | 13.6 | 13.3 | 59,819 |
| white blood cell count decreasedSignal | 3,845 | 12.3 | 12.0 | 38,875 |
| alopeciaSignal | 3,711 | 6.5 | 6.3 | 16,984 |
| arthralgiaSignal | 4,046 | 3.3 | 3.2 | 6,550 |
| fatigueSignal | 7,561 | 3.3 | 3.2 | 12,415 |
| astheniaSignal | 3,034 | 2.7 | 2.6 | 3,362 |
| diarrhoeaSignal | 4,792 | 2.5 | 2.4 | 4,463 |
| nauseaSignal | 5,594 | 2.4 | 2.3 | 4,667 |
| vomitingSignal | 2,820 | 2.0 | 2.0 | 1,489 |
| dyspnoea | 2,976 | 1.8 | 1.7 | 1,028 |
| pain | 3,097 | 1.7 | 1.6 | 918 |
| headache | 2,537 | 1.4 | 1.3 | 253 |
| death | 2,738 | 1.1 | 1.0 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.